[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343079-105":59,"doc-detail-343079-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","anti-egfr-antibodydrug-conjugate-carrying-an-inhibitor-targeting-cdk-restricts-triple-negative-breast-cancer-growth","Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth","","Anti-EGFR antibodies show limited response in breast cancer, partly driven by compensatory pathway activation. While cyclin-dependent kinase (CDK) 4/6 inhibitors succeed in hormone receptor–positive disease, aggressive triple-negative breast cancer (TNBC) often resists therapy through CDK2/cyclin E expression, and free CDK2 inhibition is constrained by normal tissue toxicity. A cetuximab-based antibody drug conjugate delivering an oncogene-dysregulation-selected CDK inhibitor, SNS-032, was evaluated for EGFR-targeted delivery and subgroup stratification. Multi-omics, imaging, and xenograft studies indicate CDK2 and cyclin partners are expressed in basal-like/TNBC linked to EGFR, and the ADC restricts tumor growth despite a small inhibitor fraction.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anti-egfr-antibodydrug-conjugate-carrying-an-inhibitor-targeting-cdk-restricts-triple-negative-breast-cancer-growth/343079/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anti-egfr-antibodydrug-conjugate-carrying-an-inhibitor-targeting-cdk-restricts-triple-negative-breast-cancer-growth/343079.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do anti-EGFR antibodies show limited effectiveness in breast cancer?","Question",{"text":112,"@type":113},"Their response is limited partly due to activation of compensatory pathways. The study also highlights resistance features within aggressive subtypes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the antibody-drug conjugate (ADC) designed in this work?",{"text":117,"@type":113},"Cetuximab was conjugated with the CDK inhibitor SNS-032 to enable specific delivery to EGFR-expressing cells, targeting CDK-driven cell-cycle regulation in TNBC.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings regarding tumor inhibition by the ADC?",{"text":121,"@type":113},"The ADC inhibited cell-cycle progression, induced cytotoxicity in high-EGFR tumor cells, and produced bystander killing in neighboring EGFR-low cells, while showing minimal effects on immune cells and restricting EGFR-expressing tumor growth in models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343079,1790810162,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth  \nAnthony Cheung1,2, Alicia M. Chenoweth1,2, Annelie Johansson1,3, Roman Laddach2,4, Naomi Guppy5, Jennifer Trendell1, Benjamina Esapa2, Antranik Mavousian5, Blanca Navarro-Llinas1, Syed Haider5,  \nPablo Romero-Clavijo2, Ricarda M. Hoffmann2,5, Paolo Andriollo6, Khondaker M. Rahman6, Paul Jackson6, Sophia Tsoka4, Sheeba Irshad1, Ioannis Roxanis5, Anita Grigoriadis1,3, David E. Thurston6, Christopher J. Lord5, Andrew N. J. Tutt1,5, and Sophia N. Karagiannis1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Anti-EGFR antibodies show limited response in breast cancer, partly due to activation of compensatory pathways. Furthermore, despite the clinical success of cyclin-dependent kinase (CDK) 4/6 inhibitors in hormone receptor–positive tumors, aggressive triple-negative breast cancers (TNBC) are largely resistant due to CDK2/cyclin E expression, whereas free CDK2 inhibitors display normal tissue toxicity, limiting their therapeutic application. A cetuximab-based antibody drug conjugate (ADC) carrying a CDK inhibitor selected based on oncogene dysregulation, alongside patient subgroup stratification, may provide EGFR-targeted delivery.\u003Cbr>Experimental Design: Expressions of G1/S-phase cell cycle regulators were evaluated alongside EGFR in breast cancer. We conjugated cetuximab with CDK inhibitor SNS-032, for specific delivery to EGFR-expressing cells. We assessed ADC internalization and its antitumor functions in vitro and in orthotopically grown basal-like/TNBC xenografts.\u003Cbr>Results: Transcriptomic (6,173 primary, 27 baseline, and matched post-chemotherapy residual tumors), single-cell\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | RNA sequencing (150,290 cells, 27 treatment-nave tumors), and spatial transcriptomic (43 tumor sections, 22 TNBCs) analyses confirmed expression of CDK2 and its cyclin partners in basal-like/TNBCs, associated with EGFR. Spatiotemporal live-cell imaging and super-resolution confocal microscopy demonstrated ADC colocalization with late lysosomal clusters. The ADC inhibited cell cycle progression, induced cytotoxicity against high EGFR-expressing tumor cells, and bystander killing of neighboring EGFR-low tumor cells, but minimal effects on immune cells. Despite carrying a small molar fraction (1 . 65%) of the SNS-032 inhibitor, the ADC restricted EGFR-expressing spheroid and cell line/patient-derived xenograft tumor growth.\u003Cbr>Conclusions: Exploiting EGFR overexpression, and dysregulated cell cycle in aggressive and treatment-refractory tumors, acetuximab–CDK inhibitor ADC may provide selective and efficacious delivery of cell cycle–targeted agents to basal-like/TNBCs, including chemotherapy-resistant residual disease. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\n1Breast Cancer Now Research Unit, School of Cancer and Phar","cbCaieN0RT08ProX","https://ap.wps.com/l/cbCaieN0RT08ProX","pdf",6650232,18,"English","# Introduction\n# Purpose\n# Experimental Design\n# Results\n# Conclusions","[{\"question\":\"Why do anti-EGFR antibodies show limited effectiveness in breast cancer?\",\"answer\":\"Their response is limited partly due to activation of compensatory pathways. The study also highlights resistance features within aggressive subtypes.\"},{\"question\":\"How was the antibody-drug conjugate (ADC) designed in this work?\",\"answer\":\"Cetuximab was conjugated with the CDK inhibitor SNS-032 to enable specific delivery to EGFR-expressing cells, targeting CDK-driven cell-cycle regulation in TNBC.\"},{\"question\":\"What were the key findings regarding tumor inhibition by the ADC?\",\"answer\":\"The ADC inhibited cell-cycle progression, induced cytotoxicity in high-EGFR tumor cells, and produced bystander killing in neighboring EGFR-low cells, while showing minimal effects on immune cells and restricting EGFR-expressing tumor growth in models.\"}]","Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth | PDF",1790049787,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/176b5efc8c8049166e8f7acae1eba273.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af71d02b1ed53f8532b1dd66cfcd0463.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/778e39646fcd88e91d080f478eaa3fb6.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3088f6397df960fde5ef089f3a42758.webp",980,1311]